|Peter M. DeComo, the Chairman and Chief Executive Officer founded and shepherded Renal Solutions to a $200 million acquisition by Fresenius Medical Care. 25+ years of life sciences start up experience. Director of the Pittsburgh Life Sciences Greenhouse & Pittsburgh Tech Council. Former practicing respiratory therapist and critical care faculty member at the University of Pittsburgh School of Medicine.|
|David J. Haffner, Executive Vice President, CFO & COO,
20 years of medical device executive management experience. Previously CFO of Foundation Radiology, ClearCount Medical Solutions, Renal Solutions, and NOMOS Corp.
|Joseph Argyros, Senior Vice President – Operations
30 years of Product Development, Operations, and Commercialization experience in early stage medical device. Held executive management positions at NOMOS, Neuro-Kinetics, and SATEC Systems.
|Frank J. Falcione, Senior Vice President – Regulatory Affairs and Quality Assurance
28 years of domestic and internal medical device regulatory and quality experience, including 510K, PMA, IDE, ISO and CE Mark approvals. Former VP Technology at CHS Business Associates.
|Jeremy D. Kimmel, PhD, Vice President of New Technology
15+ years in medical device R&D, expertise in cardiopulmonary devices, pre-clinical and clinical research and product development. Adjunct Prof. Bioengineering at Univ. of Pittsburgh with expertise in academic technology commercialization and intellectual property.
|Laura W. Lund, PhD, Vice President – Clinical Science
20 years experience in the research, design and validation of blood gas exchange technology and the science of its clinical application. Former Assistant Professor of Bioengineering at Univ. of Pittsburgh.
|Tracey Dill, Vice President Clinical Operations
20 years of Respiratory Therapy, critical care and clinical trial research experience with expertise in protocol design, regulatory compliance, study startup, CRO/investigator relationship management and commercial operations support.
|Rachel Allen, General Counsel
Former Partner at Jones Day, significant experience with venture capital and private equity-backed companies. Former General Counsel to Renal Solutions.
William Federspiel, PhD, Head of the Scientific Advisory Board and co-founder, is the Director of the Medical Devices Laboratory, McGowan Institute for Regenerative Medicine, University of Pittsburgh where he is a William Kepler Whiteford Professor of Bioengineering, Chemical Engineering, and Critical Care Medicine.
Board of Directors
Jeanne Cunicelli, a board member, is an Executive Vice President of UPMC Enterprises. Ms. Cunicelli has more than two decades of investment and advising experience in the life sciences industry.
Peter M. DeComo, the Chairman and Chief Executive Officer founded and shepherded Renal Solutions to a $200 million acquisition by Fresenius Medical Care in late 2007. In addition, he is a registered respiratory therapist, and has an extensive background in extracorporeal therapies.
Gary G. Glausser, a board member, is the Chief Investment Officer of Innovation Works (IW). Gary oversees IW’s investment fund(s), chairs its Investment Committee and helps IW source, evaluate and invest in the region’s most promising startups. He is also General Partner at Birchmere Ventures, a fully invested venture capital fund with $160 million under management. Mr. Glausser has over 30 years experience in financial management, investing, lending, and public accounting.
John A. Kuzmishin, a board member, is President of Rundle Advisors, an independent consultancy working with companies and investors in the healthcare sector. Prior to Rundle Advisors, John was most recently EVP of UPMC Enterprises. Prior to UPMC, John was in investment banking as Managing Director with Robert W. Baird & Co. and VP with Vector Securities International, both in Chicago.
Kraig McEwen, a board member, is Executive Chairman of TrellisRx. Previously he was the CEO of Aesynt Inc., formerly McKesson Automation, Inc. (MAI). Prior to Aesynt, Mr. McEwen was President and CEO of CardiacAssist and Senior Vice President of Medrad Inc.
David Motley, a board member, is a General Partner at Blue Tree Venture Fund. He is also a Senior Managing Director at Headwaters|SC, and former VP and GM at Respironics and Covidien.
Dr. Adam Seiver, MD, PhD, a board member, is Chief Medical Officer of Philips Patient Care and Monitoring Systems. Prior to joining industry—Respironics in 2003, and then Philips via acquisition in 2008—he practiced trauma surgery and surgical intensive care for 20 years on the faculty of the Department of Surgery at Stanford Medical School, in Palo Alto, California. His current clinical practice involves critical care telemedicine, directing the 161-bed eICU program (VISICU/Philips) of the Sutter Health System, Sacramento, California.